Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
As for March 26, 2020
1.BCG Vaccine Clinical Experiment for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.
The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.
2.Introduce of VPM1002，a Genetically Modified More Effective BCG Vaccine
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.
The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.
Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.
3.Research Progress for VPM1002
Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.
The vaccine is currently being tested in a further Phase III study on adult volunteers in India.
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from 0-5 Years Old and 5-18 Years Old are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 key manufacturers include Vakzine Projekt Management (VPM) and Serum Institute of India etc. Vakzine Projekt Management (VPM), Serum Institute of India, are top 3 players and held % sales share in total in 2022.
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 can be divided into 0.5ml Package, 1ml Package, 2ml Package and Other, etc. 0.5ml Package is the mainstream product in the market, accounting for % sales share globally in 2022.
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 is widely used in various fields, such as 0-5 Years Old, 5-18 Years Old, 18-45 Years Old and 45-65 Years Old, etc. 0-5 Years Old provides greatest supports to the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry development. In 2022, global % sales of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 went into 0-5 Years Old filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Vakzine Projekt Management (VPM)
Serum Institute of India
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 introduction, etc. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
1.BCG Vaccine Clinical Experiment for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.
The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.
2.Introduce of VPM1002，a Genetically Modified More Effective BCG Vaccine
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.
The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.
Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.
3.Research Progress for VPM1002
Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.
The vaccine is currently being tested in a further Phase III study on adult volunteers in India.
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from 0-5 Years Old and 5-18 Years Old are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 key manufacturers include Vakzine Projekt Management (VPM) and Serum Institute of India etc. Vakzine Projekt Management (VPM), Serum Institute of India, are top 3 players and held % sales share in total in 2022.
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 can be divided into 0.5ml Package, 1ml Package, 2ml Package and Other, etc. 0.5ml Package is the mainstream product in the market, accounting for % sales share globally in 2022.
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 is widely used in various fields, such as 0-5 Years Old, 5-18 Years Old, 18-45 Years Old and 45-65 Years Old, etc. 0-5 Years Old provides greatest supports to the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry development. In 2022, global % sales of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 went into 0-5 Years Old filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Vakzine Projekt Management (VPM)
Serum Institute of India
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 introduction, etc. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices